The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis
Open accessAbstract
In drug development, there are typically a series of preclinical studies that must be completed with new compounds or regimens before use in humans. A sequence of in vitro assays followed by in vivo testing in validated animal models to assess the activity against Mycobacterium tuberculosis, pharmacology and toxicity is generally used for advancing compounds against tuberculosis in a preclinical stage. A plethora of different assay systems and conditions are used to study the effect of drug candidates on the growth of M. tuberculosis, making it difficult to compare data from one laboratory to another. The Bill and Melinda Gates Foundation recognized the scientific gap to delineate the spectrum of variables in experimental protocols, identify which of these are biologically significant, and converge towards a rationally derived standard set of optimized assays for evaluating compounds. The goals of this document are to recommend protocols and hence accelerate the process of TB drug discovery and testing. Data gathered from preclinical in vitro and in vivo assays during personal visits to laboratories and an electronic survey of methodologies sent to investigators is reported. Comments, opinions, experiences as well as final recommendations from those currently engaged in such preclinical studies for TB drug testing are being presented. Certain in vitro assays and mouse efficacy models were re-evaluated in the laboratory as head-to-head experiments and a summary is provided on the results obtained. It is our hope that this information will be a valuable resource for investigators in the field to move forward in an efficient way and that key variables of assays are included to ensure accuracy of results which can then be used for designing human clinical trials. This document then concludes with remaining questions and critical gaps that are in need of further validation and experimentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Collins, L., & Franzblau, S. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1004 · Cited by 1,599
Self-citationA replication clock for Mycobacterium tuberculosis
Gill, W. P., Harik, N. S., Whiddon, M. R., Liao, R. P., Mittler, J. E., & Sherman, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1915 · Cited by 341
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis
Siddiqi, S. H., Libonati, J. P., & Middlebrook, G. (1981) · Journal of Clinical Microbiology · doi:10.1128/jcm.13.5.908-912.1981 · Cited by 242
Translating animal research into clinical benefit
Hackam, D. G. (2007) · BMJ · doi:10.1136/bmj.39104.362951.80 · Cited by 157
Andreu, N., Fletcher, T., Krishnan, N., Wiles, S., & Robertson, B. D. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr472 · Cited by 115
Cited by
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4683 · Cited by 607
Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
Self-citationPredicting Mouse Liver Microsomal Stability with “Pruned” Machine Learning Models and Public Data
Perryman, A. L., Stratton, T. P., Ekins, S., & Freundlich, J. S. (2016) · Pharmaceutical Research · doi:10.1007/s11095-015-1800-5 · Cited by 50
Gao, C., Peng, C., Shi, Y., You, X., Ran, K., Xiong, L., Ye, T.-H., Zhang, L., Wang, N., Zhu, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep29717 · Cited by 48
Animal models in tuberculosis research – where is the beef?
Myllymäki, H., Niskanen, M., Oksanen, K. E., & Rämet, M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1049529 · Cited by 44
Metadata
- Authors
- Franzblau, S. G., DeGroote, M. A., Cho, S. H., Andries, K., Nuermberger, E., Orme, I. M., Mdluli, K., Angulo-Barturen, I., Dick, T., Dartois, V., & Lenaerts, A. J.
- Venue
- Tuberculosis
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 92
- Issue
- 6
- Pages
- 453-488
- ISSN
- 1472-9792 (ISSN-L)
- OpenAlex
- W1967396133
- Cited by
- 217
- References
- 6
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. https://app.cochat.ai/papers/10.1016/j.tube.2012.07.003
- The paper
- Franzblau, S. G., DeGroote, M. A., Cho, S. H., Andries, K., Nuermberger, E., Orme, I. M., Mdluli, K., Angulo-Barturen, I., Dick, T., Dartois, V., & Lenaerts, A. J. (2012). Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis. https://doi.org/10.1016/j.tube.2012.07.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.